Mwanzo5CV • FRA
add
CureVac BV
Bei iliyotangulia
€ 3.84
Bei za siku
€ 3.88 - € 3.95
Bei za mwaka
€ 2.06 - € 4.95
Thamani ya kampuni katika soko
883.89M USD
Wastani wa hisa zilizouzwa
elfu 35.63
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (EUR) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 14.44M | 90.47% |
Matumizi ya uendeshaji wa biashara | 44.97M | -16.67% |
Mapato halisi | -72.54M | -7.61% |
Kiwango cha faida halisi | -502.51 | 43.51% |
Mapato kwa kila hisa | -0.32 | -6.67% |
EBITDA | -66.13M | 0.71% |
Asilimia ya kodi ya mapato | -1.83% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (EUR) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 202.52M | -62.35% |
Jumla ya mali | 556.84M | -38.09% |
Jumla ya dhima | 180.30M | -28.00% |
Jumla ya hisa | 376.53M | — |
hisa zilizosalia | 224.31M | — |
Uwiano wa bei na thamani | 2.28 | — |
Faida inayotokana na mali | -28.56% | — |
Faida inayotokana mtaji | -39.45% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (EUR) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -72.54M | -7.61% |
Pesa kutokana na shughuli | -89.11M | -38.99% |
Pesa kutokana na uwekezaji | -7.49M | 47.30% |
Pesa kutokana na ufadhili | -1.22M | -1.67% |
Mabadiliko halisi ya pesa taslimu | -97.64M | -22.67% |
Mtiririko huru wa pesa | -74.99M | -514.20% |
Kuhusu
CureVac N.V. is a German biopharmaceutical company. It develops therapies based on messenger RNA. Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr, Steve Pascolo, Florian von der Mulbe, Günther Jung, and Hans-Georg Rammensee. CureVac has had approximately 375 employees since May 2018.
At the beginning of the COVID-19 pandemic, CureVac was an early starter in the race to develop a German vaccine for protection against COVID-19, a disease caused by infection with the SARS-CoV-2 virus. Clinical trials for the CureVac COVID-19 Vaccine began in June 2020, and in the same month, the German Federal Government invested €300 million in CureVac, with one of the terms of the agreement being that KfW will hold a stake of approximately 23% in the company. In June 2021 the company announced that CVnCoV displayed inadequate results in Phase III clinical trials with only 47% efficacy. In October 2021, the company announced it would be abandon further research and development into CVnCoV and would instead focus its efforts in collaborating with GSK to develop improved mRNA vaccine technology. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2000
Tovuti
Wafanyakazi
1,086
